Evidence map›Paper›PMID 32019545›Full record

ReviewAIDS research and therapy2020

HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options.

S Jespersen, F Månsson, J Lindman, C Wejse, C Medina, Z J da Silva, DdS Te, P Medstrand, J Esbjörnsson, B L Hønge

Open access · goldAbstract readReview
In one paragraph

Review in AIDS research and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

S JespersenDepartment of Infectious Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark. sanne.jespersen@clin.au.dk.
F MånssonDepartment of Translational Medicine, Lund University, J Waldenströms gata 35, 205 02, Malmö, Sweden.
J LindmanDepartment of Clinical Sciences Lund, Division of Infection Medicine, Lund University, BMC F12, 221 84, Lund, Sweden.
C WejseDepartment of Infectious Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
C MedinaNational HIV Programme, Ministry of Health, Bissau, Apartado 861, 1004, Bissau Codex, Guinea-Bissau.
Z J da SilvaNational HIV Programme, Ministry of Health, Bissau, Apartado 861, 1004, Bissau Codex, Guinea-Bissau.
DdS TeNational HIV Programme, Ministry of Health, Bissau, Apartado 861, 1004, Bissau Codex, Guinea-Bissau.
P MedstrandDepartment of Translational Medicine, Lund University, J Waldenströms gata 35, 205 02, Malmö, Sweden.
J EsbjörnssonDepartment of Translational Medicine, Lund University, J Waldenströms gata 35, 205 02, Malmö, Sweden.
B L HøngeDepartment of Infectious Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Aarhus University Hospital · DKLund University · SENational Institute of Public Health · GWNuffield Orthopaedic Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in the treatment quality of HIV throughout the world, several countries are still facing numerous obstacles in delivering HIV treatment at a sufficiently high quality, putting patients' lives in jeopardy. The aim of this status article is to give an overview of HIV treatment outcomes in the West African country, Guinea-Bissau, and to assess how newer treatment strategies such as long-acting injectable drugs or an HIV cure may limit or stop the HIV epidemic in this politically unstable and low-resource setting. Several HIV cohorts in Guinea-Bissau have been established and are used as platforms for epidemiological, virological, immunological and clinical studies often with a special focus on HIV-2, which is prevalent in the country. The Bandim Health Project, a demographic surveillance site, has performed epidemiological HIV surveys since 1987 among an urban population in the capital Bissau. The Police cohort, an occupational cohort of police officers, has enabled analyses of persons seroconverting with estimated times of seroconversion among HIV-1 and HIV-2-infected individuals, allowing incidence measurements while the Bissau HIV Cohort and a newer Nationwide HIV Cohort have provided clinical data on large numbers of HIV-infected patients. The HIV cohorts in Guinea-Bissau are unique platforms for research and represent real life in many African countries. Poor adherence, lack of HIV viral load measurements, inadequate laboratory facilities, high rates of loss to follow-up, mortality, treatment failure and resistance development, are just some of the challenges faced putting the goal of "90-90-90″ for Guinea-Bissau well out of reach by 2020. Maintaining undetectable viral loads on treatment as a prerequisite of a cure strategy seems not possible at the moment. Thinking beyond one-pill-once-a-day, long-acting antiretroviral treatment options such as injectable drugs or implants may be a better treatment option in settings like Guinea-Bissau and may even pave the way for an HIV cure. If the delivery of antiretroviral treatment in sub-Saharan Africa in a sustainable way for the future should be improved by focusing on existing treatment options or through focusing on new treatment options remains to be determined.

Indexed as

Africa South of the SaharaAnti-HIV AgentsCohort StudiesGuinea-BissauHIV-1HIV-2HIV InfectionsHumansIncidenceTreatment FailureViral LoadAnti-HIV AgentsAntiretroviral treatmentDual infectionGuinea-BissauHIV-1HIV-2West Africa

Identifiers

PMID32019545
PMCPMC6998355
OpenAlexW3009716295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.